StreetInsider.com News Articles

United Therapeutics Corp. (UTHR) PT Raised to $566 at Morgan Stanley

Wed, 07 Oct 2026 07:59:33 -0400

Morgan Stanley analyst Terence Flynn raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $566.00 (from $515.00) while maintaining a Equalweight rating.

Form 4 UNITED THERAPEUTICS Corp For: Oct 05 Filed by: ROTHBLATT MARTINE A

Tue, 06 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261006/27155963.html

Form 4 UNITED THERAPEUTICS Corp For: Oct 02 Filed by: ROTHBLATT MARTINE A

Mon, 05 Oct 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20261005/27149557.html

Form 4 UNITED THERAPEUTICS Corp For: Oct 01 Filed by: ROTHBLATT MARTINE A

Fri, 02 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261002/27142896.html

Form 4 UNITED THERAPEUTICS Corp For: Oct 01 Filed by: MAHON PAUL A

Thu, 01 Oct 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20261001/27137379.html

Form 4 UNITED THERAPEUTICS Corp For: Sep 30 Filed by: ROTHBLATT MARTINE A

Thu, 01 Oct 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20261001/27137284.html

Form 4 UNITED THERAPEUTICS Corp For: Sep 30 Filed by: ROTHBLATT MARTINE A

Thu, 01 Oct 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20261001/27137266.html

Form 144 UNITED THERAPEUTICS Corp Filed by: ROTHBLATT MARTINE A

Thu, 01 Oct 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20261001/27136681.html

Form 144 UNITED THERAPEUTICS Corp Filed by: MAHON PAUL A

Thu, 01 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261001/27135951.html

Cantor Fitzgerald on United Therapeutics Corp. (UTHR): 'The Path to $1,000 Just Got Easier'

Thu, 01 Oct 2026 06:32:50 -0400

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $700.00 price target on United Therapeutics Corp. (NASDAQ: UTHR)

The analyst comments "We’re back to tell you how much we like UTHR (again). This was already one of our favorite stocks heading into 2027. Today’s IP surprise just made it a whole lot easier to own between now and then. And yes, we still think this can be a $1,000 stock. The important part of today's (09/30) ruling is: UTHR won on the two ’327 patent claims that matter (including the claim specifically covering a dry-powder inhaler), and LQDA (not covered)

BTIG Upgrades United Therapeutics Corp. (UTHR) to Buy

Thu, 01 Oct 2026 05:57:08 -0400

BTIG analyst Julian Harrison upgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Buy with a price target of $728.00.

The analyst comments "Our view is that the initial ‘327 trial decision is highly jeopardizing to Yutrepia’s (Liquidia [LQDA, Neutral]) freedom to operate in PH-ILD (expected patent expiration: 2042), and could also disrupt near-term PAH growth if the Judge ultimately concludes that an immediate stop is necessary across indications before PH-ILD is officially removed from Yutrepia’s label. Since launch at risk in June 2025, Yutrepia has likely hindered growth of the Tyvaso franchise, although UTHR receiving favorable initial decisions from the

BTIG Upgrades United Therapeutics Corp. (UTHR) to Buy

Thu, 01 Oct 2026 05:57:08 -0400

BTIG analyst Julian Harrison upgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Buy with a price target of $728.00.

BTIG Upgrades United Therapeutics Corp. (UTHR) to Buy

Thu, 01 Oct 2026 05:57:08 -0400

BTIG analyst Julian Harrison upgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Buy with a price target of $728.00.

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

Wed, 30 Sep 2026 19:09:00 -0400

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).

“We are pleased with the Court’s decision, which reinforces our significant research and commitment to bring innovative therapies to the patients we serve. Our immediate priority is ensuring that no patient goes without the

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

Wed, 30 Sep 2026 19:09:00 -0400

Form 4 UNITED THERAPEUTICS Corp For: Sep 29 Filed by: ROTHBLATT MARTINE A

Wed, 30 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260930/27129033.html

Liquidia shares crater after court rules for United Therapeutics

Wed, 30 Sep 2026 13:56:17 -0400

Investing.com -- Liquidia Corp shares fell Wednesday after a U.S. District Court in Delaware ruled the company infringed two patent claims held by United Therapeutics Corp. United Therapeutics shares rose more than 13%.

The court determined that claims 1 and 14 of U.S. Patent No. 11,826,327 were valid and infringed by Liquidia. These claims cover treatment of pulmonary hypertension with interstitial lung disease using inhaled treprostinil, including dry powder formulations. The court invalidated the remaining four claims asserted against Liquidia.

The parties must submit a proposed judgment, including remedies, to the court within one week. United

Liquidia shares crater after court rules for United Therapeutics

Wed, 30 Sep 2026 13:56:17 -0400

The parties must submit a proposed judgment, including remedies, to the court within one week. United

Court rules two patent claims valid against Liquidia in UTHR lawsuit